Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study.

European heart journal. Cardiovascular pharmacotherapy - 2 May 2025

Le Nhu Ngoc, Tran Tran Quoc Bao, McClure John, Gill Dipender, Padmanabhan Sandosh

Abstract excerpt

AIMS: Emerging antihypertensive drug classes offer new opportunities to manage hypertension; however, their long-term effects on cardiovascular, kidney, and metabolic (CKM) outcomes remain to be elucidated. This study aims to explore the effects of phosphodiesterase type 5 inhibitors (PDE5i), soluble guanylate cyclase stimulators (sGCs), endothelin receptor antagonists (ERAs), and angiotensinogen inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Blood Pressure

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Diseases

Share to Hypertension

Share to Kidney

Share to Mendelian Randomization Analysis

Share to Risk Assessment

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39963705
DOI: 10.1093/ehjcvp/pvaf015
PMCID: PMC12046581

Genes

CAD
CKM
PDE5A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study.PMID 39963705Read ↗

Triangulating Evidence for Antihypertensive Drug Class Efficacy on Cardiovascular and Metabolic Outcomes Using Mendelian Randomisation and ColocalisationSemantic proximity Read ↗

Cardiometabolic drugs and kidney function – a drug target Mendelian randomisation studySemantic proximity Read ↗

Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study.Semantic proximity Read ↗

Genetically proxied inhibition of angiotensinogen synthesis is associated with lower cardiovascular riskSemantic proximity Read ↗

Comprehensive Druggable Genome-Wide Mendelian Randomization Reveals Therapeutic Targets for Kidney DiseasesSemantic proximity Read ↗

Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation studySemantic proximity Read ↗

Primary Aldosteronism and Risk of Cardiovascular Outcomes: Genome-Wide Association and Mendelian Randomization Study.Semantic proximity Read ↗

A phenome-wide association and factorial Mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes.Semantic proximity Read ↗

Cardiorenal Outcomes with Finerenone in Patients Post-Acute Myocardial Infarction: Insights from a Global Federated NetworkSemantic proximity Read ↗

Using Mendelian randomization study to assess the renal effects of antihypertensive drugsSemantic proximity Read ↗

Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies.Semantic proximity Read ↗

Proteome-wide mendelian randomization identifies novel therapeutic targets for chronic kidney disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.